Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024. The management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day. The presentation will include financial results and company updates, with dial-in numbers provided for both local and international participants. A live webcast with slides will be available on the company's investor website, with an archived version accessible approximately two hours after the event.

-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET --

NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quarter-2024-financial-results-on-november-5-2024-302292411.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) report Q3 2024 earnings?

Karyopharm will report its third quarter 2024 financial results on Tuesday, November 5, 2024.

What time is Karyopharm's (KPTI) Q3 2024 earnings call?

Karyopharm's Q3 2024 earnings conference call is scheduled for 8:00 a.m. ET on Tuesday, November 5, 2024.

How can I access Karyopharm's (KPTI) Q3 2024 earnings call?

You can access the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international), or view the webcast on Karyopharm's investor website.